COAG · Hemab Therapeutics Holdings, Inc.
$54.94
+0.99 (+1.84%)
At close · Aug 14
Market Cap
$2.57B
Shares
46.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$54.94
Open$53.76
Day$50.59–55.42
Available close range$24.98–54.94
Avg vol 30d394K
Short int2.0M · 4.4% float · 4.3d
Short vol75%
Last earningsAug 11, 2026
DataMay 2026–Aug 2026
Filing10-Q · Aug 11
The closing range uses available history since May 1, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+41%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+55 funds added
Insider flow
Accumulating
Net +$1.8M over 90 days · 0% sells
Short interest
Rising
4.36% of float · ▲ +22.9% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
55 holders — 13F breadth
Squeeze score
70
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
99%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
7.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+41%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+55 funds added
Insider flow
Accumulating
Net +$1.8M over 90 days · 0% sells
Short interest
Rising
4.36% of float · ▲ +22.9% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
55 holders — 13F breadth
Price context
position in its available closing range
Range low $25
Now $55 · 100%
Range high $55
vs 50-day avg +41%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COAG
this stock
Hemab Therapeutics Holdings, Inc.
|
$2.57B | — | — | — | 4.4% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COAG | +10.6% | +11.5% | — | +15.5% | — |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +10.2% | +7.0% | — | +11.6% | — |
Key facts
CIK
2114044
CUSIP
423494103
13F (30d)
61 filings
57 filers
Visit website
Investor relations